This study will assess the effect of food (high fat) on oral ABBV-101 and how ABBV-101 moves through the body in healthy adult participants
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
17
Oral: Tablet
Acpru /Id# 275921
Grayslake, Illinois, United States
Number of Participants Experiencing Adverse Events
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment
Time frame: Up to approximately 45 days
Maximum Observed Plasma Concentration (Cmax) of ABBV-101
Maximum observed plasma concentration (Cmax) of ABBV-101
Time frame: Up to approximately 21 days
Time to Cmax (Tmax) of ABBV-101
Tmax of ABBV-101
Time frame: Up to approximately 21 days
Area Under the Plasma Concentration-Time Curve (AUC) of ABBV-101
AUC of ABBV-101
Time frame: Up to approximately 21 days
Terminal Phase Elimination Half-life (t1/2) of ABBV-101
Terminal phase elimination of half-life (t1/2) of ABBV-101
Time frame: Up to approximately 21 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.